Phase 3 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with hairy cell leukemia, confirmed through a laboratory examination of their tissue samples
- People whose hairy cell leukemia has been detected in the bone marrow and blood using specific laboratory tests that look for certain markers on the cells
- People who have not previously received chemotherapy for this condition (though prior spleen removal surgery or interferon treatment is acceptable)
- People who currently need treatment for their condition
- People who are at least 18 years old
- People whose general health is rated at a reasonable level according to a standard medical scale (confirm with trial site)
- People who have had a recent tissue examination done within the last 6 months
- People who are willing and able to provide written agreement to take part
Who may not be able to join:
- People who have a specific variant of hairy cell leukemia called HCL-V, which involves cells that look slightly different under the microscope and show a different pattern of laboratory markers
- People who have previously been treated with a type of chemotherapy called purine analogues or any other chemotherapy drugs
- People who are currently taking steroid medications (corticosteroids)
- People who have serious problems with their heart, lungs, liver, or kidneys, or who have significant conditions affecting the brain or mental health
- People who have a confirmed HIV infection
- People who have active hepatitis (liver inflammation caused by infection)
- People who have another active infection
- People who have been diagnosed with another type of cancer, unless it is a non-melanoma skin cancer or an early-stage cervical condition that has not spread
- Women who are pregnant or breastfeeding
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Mathias J Rummel, Prof. Dr., Justus-Liebig-University | University Hospital | Medicinal Clinic IV
Phone: +4964198542
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Determination of the rate of complete remissions after one cycle with subcutaneous cladribine
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.